Analysis File of Drug-Induced Lung Injury

​Akihiko GemmaPresident, Nippon Medical School 1983:Graduated from the Faculty of Medicine of Nippon Medical School1986:Served as a trainee doctor in the Pathology Department of the National Cancer Center Research Institute1989:Graduated from Nippon Medical School Graduate School1995:Studied at National Cancer Institute of National Institutes of Health (NIH), the United States1998:Appointed as a lecturer to Nippon Medical School2004:Appointed as an associate professor2008:Appointed as a senior professor to the Department of Medicine (Respiratory, Infectious Disease and Oncology Division)2012:Appointed as a professor to the Graduate School of Medicine in charge of respiratory medicine2013:Appointed dean of Department of Medicine2015：Appointed president

Part I Understanding Drug-Induced Lung Injuries.- 1 Understanding Drug-Induced Lung Injuries.- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug.- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib).- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab).- 4 mTOR inhibitors (temsirolimus, everolimus).- 5 Proteasome inhibitor (bortezomib).- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab).- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab).- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.).- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan).- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).